MIRA
INFORM REPORT
|
Report Date : |
26.07.2007 |
IDENTIFICATION DETAILS
|
Name : |
BIOMARDON PHARMA OOO |
|
|
|
|
Registered Office : |
Business Centre Inconel, Office 400, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
2005 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturers of pharmaceutical products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
COmpany NAME
BIOMARDON PHARMA OOO
(Correct)
BIO MARDON PHARMA
(Requested)
ADDRESS
Building :
Business Centre Inconel, office 400
Street :
Town :
Country :
Telephone :
(998 71) 131 5377 / 159 6111 / (97) 119 0630 (mobile)
Fax : (998 71) 131 5377
E-Mail : biomardon@yandex.ru
SENIOR COMPANY
PERSONNEL
Name Position
1. Mardon Shukurov Managing
Director
2. Khamidulla Kenzhaev Deputy
Managing Director
3. Shakhista
Shakhidova Manager
Total Employees
5 (administrative)
PAYMENTS
Current experience of
payments has not been traced.
Subject declined to give
any financial, general background or antecedent information or to reveal the
extent of the company's operations.
Opinion on maximum credit
: We have insufficient basis on which to speak for unsecured credit and
recommend international suppliers deal on cash or prepaid basis only.
Trade risk assessment :
High
It is normal accepted
practice for international suppliers to deal on secured terms with
PRINCIPAL BANKERS
Subject declined to name
its bankers.
FINANCIAL INFORMATION
Private companies in
LEGAL STATUS AND HISTORY
Date Started : 2005
History : Originally
established in
Capital : not given
Obshchestvo s
Ogranichennoy Otvetstvennostyu (limited liability company) with the following
sole shareholder :
Mardon Shukurov 100%
ACTIVITIES
The Company is involved
in the following activities :
Manufacturers of pharmaceutical
products.
Subject does not import
any products at present.
FACILITIES
The Company has the
following facilities :
Office premises located
at the heading address and manufacturing unit located elsewhere in
SPECIAL NOTE
You enquired on : BIO
MARDON PHARMA. Please note the correct name is as per heading.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)